By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD202 - Peter on nutrition, disease prevention, and more — looking back on the last 100 episodes
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:11 – 8:33
Strong Convictions, Loosely Held: Framing the Episode
Peter introduces the special episode looking back at the last 100 episodes, and the host explains the AMA-style format. Peter then explains where the phrase 'strong convictions, loosely held' came from and why changing your mind matters in science and medicine.
- •Episode looks back at episodes 100 to 200 to see where views changed or strengthened
- •Peter credits the phrase to a friend, John Griffin, a former hedge fund manager
- •Updating assumptions with new information is treated as a strength, though it's often seen as weakness
- •Peter says this is part of why he's wary of print, since a book locks in a point of view
- 8:33 – 14:46
Peter's Book Update: Cutting Words and the Audiobook Question
The host asks about the book manuscript. Peter explains it is being cut from about 200,000 words toward 120,000, talks about 'killing your babies,' and explains why he doesn't want to read the audiobook himself.
- •Editor at Penguin Random House initially suggested about 80,000 words; the target is around 120,000
- •Co-author Bill Gifford and Peter push each other to say things in fewer words
- •'Kill your babies' advice came from his early lab experience writing a scientific paper
- •Peter doesn't want to narrate the audiobook because it would take two weeks and he is a poor reader
- •Anecdote about his son memorizing a water cycle book
- 14:46 – 24:34
Cancer: The Promise of Immunotherapy
Peter explains how the Steve Rosenberg episode changed his view of immunotherapy, focusing on the finding that 80% of patients have neoantigens recognized by the immune system. He predicts designer immunotherapies could eradicate most metastatic solid tumors in about 10 years, and the host asks him to define terms and timeline.
- •80% of patients have neoantigens recognized by their immune system
- •IL-2 and checkpoint inhibitors help only a narrow subset of patients
- •TIL and adoptive cell therapy could extend benefit, making it partly a bioengineering problem
- •Cost may be less than current cancer drugs on a quality-adjusted life year basis
- •Metastasis and inability to respond to growth-stop signals are the two hallmarks of cancer cells
- •Ten years may mean out of clinical trials but not necessarily covered by insurance
- 24:34 – 31:46
Cancer: Aggressive Screening for GI Cancers
Peter explains why he is very aggressive about screening for gastrointestinal cancers, arguing colon cancer deaths should be preventable because polyps are visible and removable. He discusses the costs and risks of colonoscopy, the interval he favors, and starting at 40.
- •About 170,000 of roughly 600,000 US cancer deaths are in the digestive system
- •The thought experiment: a daily colonoscopy would prevent colon cancer
- •He suggests colonoscopy every one to three years rather than every five to ten
- •Costs include money, sedation risk and perforation risk, which are small
- •His practice starts first colonoscopy at 40
- 31:46 – 40:21
ASCVD: Treating ApoB Early and Aggressively
Peter explains he has become far more aggressive about the timing and magnitude of ApoB reduction. He proposes very low ApoB targets, gives percentile reference numbers, and outlines the therapeutic options.
- •ApoB captures the total concentration of atherogenic lipoproteins and is better than LDL-C or non-HDL-C
- •He now argues infant-like ApoB levels (30-40 mg/dL) are not harmful, so waiting for an issue is a mistake
- •Thought experiment: lowering ApoB to 20-30 mg/dL in one's 20s could effectively eliminate ASCVD
- •He would want ApoB below roughly 60, the fifth percentile, by late 30s or early 40s
- •Statins, PCSK9 inhibitors, ezetimibe and bempedoic acid give many options
- •Patients should ask their doctor to order ApoB
- 40:21 – 44:24
Alzheimer's Disease: Genes That Modify APOE4 Risk
Peter says his focus on Alzheimer's has shifted to genes beyond APOE that modify risk. He describes the APOE genotype risks, modifiers such as TOMM40, mitochondrial haplotypes and klotho, and the difficulty of testing for them.
- •APOE 3/4 carries about 2-3x risk and 4/4 about 8-12x at the population level
- •Some 4/4 individuals don't get the disease early, so other genes must modify risk
- •TOMM40 and mitochondrial haplotypes amplify risk
- •A klotho variant seems to erase the APOE4 downside
- •Testing is brute force, takes months, and a goal is getting costs below $20,000 per person
- 44:24 – 55:04
Nutrition: Time-Restricted Feeding and Protein Underconsumption
Peter says he now believes most of time-restricted feeding's benefit comes from caloric restriction, and that it can be problematic when people lose lean mass. He explains using DEXA to track muscle, and argues protein RDAs are far too low, with deficits especially in middle-aged women.
- •No evidence of a magical effect beyond reduced calories in a shorter window
- •Aggressive TRF or OMAD can cost lean mass while adding fat and worsening glucose control
- •DEXA is the practical tool; FFMI, ALMI and visceral fat matter more than total body fat percent
- •RDA of 0.8 g/kg reflects survival, while he thinks closer to 2 g/kg is better
- •Toxicity concerns arise only around 3-4 g/kg
- 55:04 – 1:00:00
Exercise: Cardiorespiratory Fitness, Strength and Grip
Peter explains why he is more convinced than ever of exercise's effect on lifespan and healthspan, citing all-cause mortality data across VO2 max strata. He discusses grip strength as a proxy for longevity and how he trains it, and notes exercise is both the most accessible and hardest tool.
- •Moving up VO2 max categories reduces all-cause mortality more than other interventions compared
- •Peter acknowledges genetic and healthy-user confounders
- •Strength matters more than muscle mass, and grip strength is a great proxy
- •Grip is trained by carrying heavy things, farmer's carries and dead hangs
- •Exercise is available to everyone but is the hardest, most time-consuming and most uncomfortable
- 1:00:00 – 1:06:20
Peter's Shoulder Surgery and Recovery Plan
Peter describes the labrum repair on his right shoulder, done two days earlier after years of subluxations. He outlines the eight-to-nine-month recovery, with gentle early phases, lower body work and blood flow restriction training.
- •Labrum tear resulted from repeated subluxations over about 25 years
- •Expected recovery is eight to nine months
- •Early weeks involve walking and Zone 2 on a Peloton because it's easier to sit upright
- •He fears loss of mobility after being hypermobile
- •Plan includes early mobilization, KAATSU blood flow restriction and isometrics
- 1:06:20 – 1:13:21
Molecules: Skepticism on NAD Precursors and Caution on Psychedelics
Peter says he is even less optimistic about NAD precursors, noting that while NAD levels can be raised, no phenotypic benefit has been shown outside pathological states. He then voices caution about treating psychedelics as stand-alone cures, emphasizing psychotherapy, and notes promising MDMA phase three data.
- •NR and NMN can raise NAD levels, but benefit in normal aging isn't demonstrated
- •He wants good data, not cherry-picked small exploratory trials
- •Psychedelics like psilocybin and MDMA are tools to prime deeper therapeutic work
- •Psychotherapy is probably the most powerful tool, with DBT cited as an example
- •MDMA phase three trials show impressive PTSD improvements with no toxicity
- 1:13:21 – 1:20:38
Sleep: Blue Light Rethink and Trazodone
Peter says he is less worried about electronic light before bed than before, suggesting stimulating content matters more. After Phenibut became hard to get, his practice turned to low-dose trazodone, which he says preserves sleep architecture, unlike Ambien.
- •Content on a phone may matter more than blue light itself
- •Phenibut was a favored sleep supplement that became hard to obtain legally in the US
- •Trazodone at 25-100 mg is used off-label, working for north of 80% of patients
- •Ambien can reduce deep sleep and impair memory
- •Trazodone lacks the dependency issues of benzodiazepines
- 1:20:38 – 1:23:27
Book Recommendation: The Comfort Crisis
Peter recommends The Comfort Crisis by Michael Easter and says he has reached out to have the author on the podcast. He summarizes its argument that modern comfort harms mental and physical health.
- •Peter is almost done with the book and likes it so much he contacted the author
- •Premise: we are never hungry, cold, hot or bored, with negative outcomes
- •The suggestion isn't to live as hunter-gatherers but to seek appropriate doses of discomfort
- 1:23:27 – 1:27:31
Formula 1: How to Watch and the Five Performance Variables
The host asks how newcomers should approach F1. Peter recommends Drive to Survive as a starting point and lays out the four factors that determine car speed plus strategy, then discusses teams and teammate dynamics.
- •Drive to Survive is a starting point, though Peter rates only some episodes as good
- •Four variables are driver, tires, engine and chassis, with strategy as the fifth
- •F1 is distinguished by cornering and downforce rather than straight-line speed
- •Ten teams with two drivers each, and team orders sometimes apply
- •Teammates are the most direct comparison for a driver
- 1:27:31 – 1:33:58
F1: Tires, Engines, Chassis and Pit Strategy
Peter explains Pirelli's tire compounds, the mandatory use of two compounds, and the roughly 25-second cost of a pit stop that drives strategy. He then covers how engine suppliers and team-built chassis differ across teams.
- •Soft, medium and hard tires are colored red, yellow and white; harder tires last longer but are slower
- •Dry races require at least two different compounds, forcing a pit stop
- •A pit stop costs about 25-26 seconds, so extra stops are only worth it with enough per-lap pace
- •Few engine manufacturers supply many teams, but each team tailors its chassis
- •IndyCar uses a common engine and chassis, which Peter finds better in some respects
- 1:33:58 – 1:50:57
F1: 2022 Rule Changes, Qualifying and Racing Strategy
Peter explains the new regulations aimed at closer racing and reduced downforce disruption, and describes the weekend schedule and qualifying format. He also discusses qualifying importance, Senna's pole record and what to watch for in race strategy such as battery and tire management.
- •Major rule changes occur every six to eight years and reshuffle the pecking order
- •Cars behave like upside-down airplanes, and following another car loses downforce
- •New rules produced more passing in the first race, but Peter thinks the E10 fuel is a dumb idea
- •Weekend runs FP1-3, then Q1-Q3, then the race; sprint qualifying was used at some races
- •Monaco is nearly impossible to pass on; Senna holds the best pole rate
- •Drivers manage tires and battery deployment, hence calls like 'push' and 'box'
- 1:50:57 – 1:57:38
F1: Season Outlook and Predictions
Peter assesses the early season after one race, noting Ferrari's strength, Red Bull's engine reliability issues and Mercedes' resilience. He discusses team and driver dynamics, then the episode wraps up.
- •Ferrari looked strongest in testing and the first race, with a one-two finish
- •Red Bull had engine failures, and Peter wonders about fuel supplier issues
- •Leclerc is an early favorite, but Verstappen and Mercedes can't be dismissed
- •Mercedes now has Hamilton and Russell as two potential winners
- •Rivalry between Toto Wolff and Christian Horner adds intrigue
